Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Kenji Maemura
Clinical Considerations When Introducing Sodium-Glucose Co-Transporter 2 Inhibition in Patients With Heart Failure
Circulation Reports
Related publications
Sodium-Glucose Co-Transporter Type-2 Inhibitors: Pharmacology and Peri-Operative Considerations
Anaesthesia
Anesthesiology
Pain Medicine
Sodium-Glucose Co-Transporter 2 Inhibition as a Mitochondrial Therapy for Atrial Fibrillation in Patients With Diabetes?
Cardiovascular Diabetology
Internal Medicine
Cardiology
Endocrinology
Cardiovascular Medicine
Metabolism
Diabetes
Inhibition of Sodium Glucose Cotransporter-2 Mitigates Heart Failure Progression in Obesity
Journal of Cardiac Failure
Cardiovascular Medicine
Cardiology
Heart Failure Prevention With Sodium‐glucose Cotransporter 2 Inhibitors
Journal of Diabetes
Endocrinology
Metabolism
Diabetes
Effects of the Dual Sodium-Glucose Linked Transporter Inhibitor, Licogliflozin Versus Placebo or Empagliflozin in Patients With Type 2 Diabetes and Heart Failure
British Journal of Clinical Pharmacology
Pharmacology
Sodium–glucose Co-Transporter 2 Inhibitors: Think Twice About Diabetic Ketoacidosis
Evaluation of the Effects of Sodium–glucose Co‐transporter 2 Inhibition With Empagliflozin on Morbidity and Mortality in Patients With Chronic Heart Failure and a Preserved Ejection Fraction: Rationale for and Design of the EMPEROR‐Preserved Trial
European Journal of Heart Failure
Cardiovascular Medicine
Cardiology
The Long-Term Efficacy of Sodium Glucose Co-Transporter 2 Inhibitor in Patients With Non-Alcoholic Fatty Liver Disease
Internal Medicine
Internal Medicine
Medicine
Sodium‐glucose Co‐transporter Type‐2 Inhibitors: Is the Message Getting Through?
Anaesthesia
Anesthesiology
Pain Medicine
